6505--RFI - DRAFT SOW for PPV 2028 Amendment to Extend Response Date from July 2, 2026 to July 10, 2026 11:00AM CT.

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NAC PRIME VENDOR (36W797)

Contract Value

Not provided

Codes & Classification
Solicitation Number

36E79726Q0003

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
The Department of Veterans Affairs (VA), through its National Acquisition Center (NAC) Prime Vendor office, is seeking industry input on the draft Statement of Work (SOW) for the Pharmaceutical Prime Vendor (PPV) 2028 acquisition. This request for information (RFI), issued under procurement identifier 36E79726Q0003, is a sources sought notice intended to solicit feedback from qualified vendors and stakeholders in the pharmaceutical preparation manufacturing sector (NAICS Code 325412, Product Service Code 6505). The primary purpose of this engagement is to refine and enhance the draft SOW, ensuring it is clear, comprehensive, and structured to foster effective competition and optimal performance in the future PPV 2028 program. The PPV 2028 initiative is designed to support the delivery of pharmaceutical products to VA medical centers nationwide, with a focus on efficient distribution operations, robust inventory management, accurate reporting, seamless data exchange, and reliable order fulfillment processes. Industry participants are invited to review the attached draft SOW, definitions, and distribution fee categories, and provide constructive feedback by identifying unclear, conflicting, or ambiguous requirements; commenting on technical or operational aspects that may impact performance; suggesting improvements to operational processes; highlighting potential risks or barriers; and recommending areas where additional clarity or definition would be beneficial. Suggestions to improve efficiency or align with industry best practices are particularly encouraged. The VA emphasizes that this notice is not a solicitation and does not obligate the government to issue a solicitation or award a contract. No contract will be awarded as a result of this notice, and participation in this review is voluntary. Furthermore, participation (or lack thereof) will not preclude any vendor from submitting a proposal in response to any future PPV 2028 solicitation. All feedback will be used strictly for market research and SOW refinement purposes, and the government will not reimburse any costs associated with providing comments or participating in related activities. Interested parties should submit their feedback via email to the primary contact, Karen Ade ([email protected], 708-786-5231), no later than 11:00 AM Central Time on July 10, 2026. Submissions should include the company name, point of contact information, UEI and CAGE Code, and any applicable socioeconomic designations. This opportunity is classified under NAICS 325412 (Pharmaceutical Preparation Manufacturing, 2022 version) and is managed by the NAC PRIME VENDOR office (organization key 100163913) within the Department of Veterans Affairs. The notice remains active and is accessible via SAM.gov (Opportunity ID: 119d0dfdcc834a38a2e082f046b36546), with eight attachments available for review. Contractors with expertise in pharmaceutical distribution and related operations are encouraged to participate in this industry review, as their input will play a critical role in shaping the requirements and objectives of the PPV 2028 program, ensuring it meets the needs of VA medical centers and supports the delivery of high-quality pharmaceutical products to veterans nationwide.
Documents8